NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,937.50 | 41.90 | -0.47% |
CAC 40 | 7,818.28 | 32.15 | -0.41% |
DAX 40 | 24,295.93 | 55.11 | 0.23% |
Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
FTSE 100 | 9,138.37 | 76.88 | 0.85% |
HKSE | 25,383.07 | 284.11 | -1.11% |
NASDAQ | 21,057.96 | 37.94 | 0.18% |
Nikkei 225 | 41,450.36 | 375.98 | -0.90% |
NZX 50 Index | 12,855.10 | 49.97 | 0.39% |
S&P 500 | 6,363.35 | 4.44 | 0.07% |
S&P/ASX 200 | 8,670.10 | 39.30 | -0.45% |
SSE Composite Index | 3,593.38 | 12.35 | -0.34% |